Jeff Yass’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.88M | Buy |
+108,500
| New | +$1.49M | ﹤0.01% | 6622 |
|
|
2026
Q1 | – | Sell |
-216,800
| Closed | -$2.73M | – | 13103 |
|
|
2025
Q4 | $2.73M | Sell |
216,800
-85,200
| -28% | -$975K | ﹤0.01% | 5048 |
|
|
2025
Q3 | $3.02M | Buy |
302,000
+210,900
| +232% | +$1.89M | ﹤0.01% | 4964 |
|
|
2025
Q2 | $737K | Sell |
91,100
-66,500
| -42% | -$501K | ﹤0.01% | 8218 |
|
|
2025
Q1 | $1.32M | Buy |
157,600
+46,200
| +41% | +$386K | ﹤0.01% | 6546 |
|
|
2024
Q4 | $882K | Buy |
111,400
+63,800
| +134% | +$535K | ﹤0.01% | 7279 |
|
|
2024
Q3 | $396K | Sell |
47,600
-26,200
| -36% | -$205K | ﹤0.01% | 9012 |
|
|
2024
Q2 | $469K | Sell |
73,800
-55,800
| -43% | -$354K | ﹤0.01% | 8421 |
|
|
2024
Q1 | $785K | Sell |
129,600
-19,600
| -13% | -$111K | ﹤0.01% | 7448 |
|
|
2023
Q4 | $906K | Buy |
149,200
+56,200
| +60% | +$250K | ﹤0.01% | 7224 |
|
|
2023
Q3 | $392K | Sell |
93,000
-600
| -0.6% | -$2.24K | ﹤0.01% | 8788 |
|
|
2023
Q2 | $290K | Buy |
93,600
+73,200
| +359% | +$156K | ﹤0.01% | 9513 |
|
|
2023
Q1 | $28.4K | Sell |
20,400
-5,900
| -22% | -$11.7K | ﹤0.01% | 11935 |
|
|
2022
Q4 | $52.3K | Sell |
26,300
-99,300
| -79% | -$223K | ﹤0.01% | 11370 |
|
|
2022
Q3 | $254K | Buy |
125,600
+40,600
| +48% | +$114K | ﹤0.01% | 10232 |
|
|
2022
Q2 | $270K | Sell |
85,000
-29,300
| -26% | -$106K | ﹤0.01% | 9845 |
|
|
2022
Q1 | $477K | Sell |
114,300
-76,800
| -40% | -$340K | ﹤0.01% | 9114 |
|
|
2021
Q4 | $915K | Sell |
191,100
-139,000
| -42% | -$693K | ﹤0.01% | 7542 |
|
|
2021
Q3 | $1.76M | Buy |
330,100
+78,900
| +31% | +$397K | ﹤0.01% | 6114 |
|
|
2021
Q2 | $1.29M | Sell |
251,200
-31,600
| -11% | -$180K | ﹤0.01% | 7053 |
|
|
2021
Q1 | $1.9M | Buy |
282,800
+16,800
| +6% | +$93.1K | ﹤0.01% | 6046 |
|
|
2020
Q4 | $1.22M | Sell |
266,000
-40,500
| -13% | -$179K | ﹤0.01% | 6248 |
|
|
2020
Q3 | $1.19M | Sell |
306,500
-13,600
| -4% | -$58.2K | ﹤0.01% | 5700 |
|
|
2020
Q2 | $1.52M | Buy |
320,100
+287,300
| +876% | +$1.18M | ﹤0.01% | 5002 |
|
|
2020
Q1 | $114K | Buy |
+32,800
| New | +$139K | ﹤0.01% | 9226 |
|
|
2019
Q3 | – | Sell |
-38,100
| Closed | -$273K | – | 10109 |
|
|
2019
Q2 | $273K | Buy |
38,100
+27,500
| +259% | +$281K | ﹤0.01% | 8504 |
|
|
2019
Q1 | $150K | Sell |
10,600
-26,800
| -72% | -$354K | ﹤0.01% | 8049 |
|
|
2018
Q4 | $506K | Buy |
+37,400
| New | +$674K | ﹤0.01% | 6007 |
|
Other funds holding AMRX
TGA
RCMNY
Jeff Yass's AMRX Position: Q2 2026 in Review
Jeff Yass reduced its Amneal Pharmaceuticals (AMRX) stake by 59% in Q2 2026, selling an estimated $422K and leaving 21,774 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #10554.
Jeff Yass first reported a position in AMRX in Q2 2018 and has held it in 30 quarters since. The position peaked at $16.7M in Q4 2025. 305 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Jeff Yass held 21,774 shares of Amneal Pharmaceuticals worth $377K as of Q2 2026.
- Jeff Yass sold 30,769 Amneal Pharmaceuticals shares in Q2 2026, an estimated $422K.
- Amneal Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10554 holding.
- Jeff Yass first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
- Jeff Yass's Amneal Pharmaceuticals position peaked at $16.7M in Q4 2025.
- 305 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.